Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are studying how casdatifan, alone or with zimberelimab, works in people with kidney cancer. The people in this study have clear cell renal cell carcinoma. Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery).
Researchers want to find the best doses of MOMA-313 alone and with olaparib in people with cancer. The people in this study have advanced castration-resistant prostate cancer (CRPC) or pancreatic cancer. CRPC is prostate cancer that has spread and keeps growing even in the absence of hormones. Their cancers also have a genetic change called HR deficiency.
Researchers want to see if ASTX727 is practical and safe for people with high-risk clonal cytopenia of undetermined significance (CCUS). With CCUS, there is a mutation (change) in one or more of the genes that help blood cells develop. People with CCUS have low levels of certain kinds of blood cells. CCUS can lead to precancerous conditions such as myelodysplastic syndrome or blood cancers such as acute myeloid leukemia.
The purpose of this study is to find the best dose of ABBV-383 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
Brentuximab vedotin (BV) plus chemotherapy with the drugs cyclophosphamide, doxorubicin, and prednisone (CHP) is a standard treatment for T-cell lymphomas that make the CD30 protein. Researchers want to see if BV with an enhanced chemotherapy regimen that includes etoposide works better in people with T-cell lymphomas.
The purpose of this study is to find the highest dose of the investigational drug PC14586 that can be given in patients with solid tumors that came back or continue to grow despite prior therapy and contain a mutation in the TP53 gene. The p53 protein produced by this gene normally tells cells when to stop dividing, but when TP53 is altered (mutated), cancer may result.
Researchers want to find the best dose of abemaciclib to combine with radiation therapy to treat advanced breast cancer. The people in this study have metastatic breast cancer that is fueled by estrogen or progesterone (hormone receptor-positive cancer). In addition, their breast cancer does not make a protein called HER2.
Researchers want to see if combining radiation therapy and immunotherapy is safe and works well for treating advanced adrenocortical cancer. The people in this study have adrenocortical cancer that spread to other parts of the body, including the liver.
Intensity-modulated pleural radiation therapy (IMPRINT) is a type of radiation therapy that specifically targets the lining of the lungs and the inner side of the ribs to stop cancer from growing. In this study, researchers are studying the safety and effectiveness of IMPRINT to one side of the chest (hemithoracic IMPRINT) to treat people with thymic cancer (cancer of the thymus gland) that has spread to the lining of the lungs and chest.
